and the international Ludwig Institute for Cancer Research (LICR) have announced a multi-year clinical research collaboration focusing on a series of tumor-associated antigens (TAAs) for use in Celldex's Antigen Presenting Cell
(APC) Targeting Technology.
The expanded peptide-specific regulatory cells shut down the autoimmune attack by preventing aggressive autoimmune cells from being stimulated by either the peptide contained in the vaccine or by any other type 1 diabetes autoantigen presented simultaneously on the same antigen presenting cell
The method involves the loading of an antigen presenting cell
with at least one tumor associated T-cell epitope attached to an immunoglobulin backbone to form an Ig-peptide molecule ("IgNP") followed by administration the IgNP in conjunction with MCT-465, a dsRNA TLR agonist adjuvant therapeutic.
SEATTLE, March 3 /PRNewswire-FirstCall/ -- Dendreon Corporation announced the publication of a manuscript titled, "CD54 is a surrogate marker of antigen presenting cell
activation" in Cancer Immunology, Immunotherapy.
Recently, MultiCell filed the patent application entitled, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell
," which covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
Michael Morse of Duke University presented data from a Phase 1, dose-escalating study of CDX-1307, the Company's lead cancer program using its proprietary Antigen Presenting Cell
(APC) targeting technology, in a poster presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
In an newsletter article released today, SmallCapInsights addresses MultiCell's most recent patent announcementCo"Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell
," and provides investors with background on the Company and opinion on its progress and potential.
The patent filing, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell
," covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
The deletion of these genes provides a proprietary vaccine platform which combines very efficient antigen delivery to, and optimal stimulation of, this key class of antigen presenting cell
The patent claims artificial antigen presenting cell
compositions that are broadly applicable to treatment methodologies capable of eliciting up- or down-modulation of an immune response in patients with a need for such modulation.
Antigen Presenting Cell
Based Immunotherapy Targeting HER2/Neu Positive Solid Tumors: Results of a Phase 1 Study of APC8024.
CD40, a receptor on the surface of antigen presenting cells
of the immune system, plays a fundamental role in the activation of both innate and adaptive immune system mechanisms.